文献速递前列腺癌

多参数磁共振与融合靶向活检诊断前列腺癌的准确性:经会阴饱和穿刺验证

Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer.
PubMed 文献 · J Urol · 2018-02-21

该回顾性研究纳入415例接受前列腺活检的男性,以经会阴模板饱和穿刺为参照,评估多参数磁共振(mpMRI)及mpMRI/经直肠超声融合靶向活检对前列腺癌的诊断准确性。结果显示,单独mpMRI不应作为分诊试验,因为存在大量临床显著前列腺癌假阴性;系统穿刺优于融合靶向活检,在前列腺癌诊断路径中仍至关重要。

要点

  • mpMRI阴性者中25.8%经饱和穿刺检出临床显著前列腺癌,mpMRI不宜单独分诊。
  • 融合靶向活检漏诊19.9%的临床显著前列腺癌,系统穿刺仍不可替代。
  • mpMRI和融合靶向活检对临床显著前列腺癌的敏感性分别为84.6%和56.7%。

核心结论

  • 单独mpMRI因临床显著前列腺癌假阴性较多,不应作为分诊试验。
  • 系统穿刺优于融合靶向活检,在前列腺癌诊断路径中仍至关重要。

研究设计与样本

  • 使用3 Tesla无直肠内线圈mpMRI,随后行经会阴模板饱和穿刺(BiopSee融合系统)。
  • 对mpMRI可疑病灶(Likert评分3-5)加做融合靶向活检。
  • 以经会阴模板饱和穿刺为参照,用McNemar检验比较检出率。

主要发现

  • 饱和穿刺和靶向活检的中位针数分别为40(范围30-55)和3(范围2-4)。
  • 124例(29.9%)mpMRI无可疑病灶者中,32例(25.8%)经饱和穿刺检出临床显著前列腺癌。
  • 291例(70.1%)Likert评分3-5者中,临床显著前列腺癌检出:靶向活检129例(44.3%),饱和穿刺176例(60.5%),联合187例(64.3%)。
  • 若仅行融合靶向活检,将漏诊58例(19.9%)临床显著前列腺癌。
  • mpMRI和融合靶向活检对临床显著前列腺癌的敏感性分别为84.6%和56.7%,阴性似然比分别为0.35和0.46。

关键数值与推荐

  • mpMRI可疑病灶定义为Likert评分3-5。
  • 临床显著前列腺癌定义为任何Gleason模式4或更高。

临床怎么用

  • 不应单独使用mpMRI作为前列腺癌分诊工具。
  • 在靶向活检基础上应保留系统穿刺,以避免漏诊临床显著前列腺癌。

局限性

  • 回顾性单中心设计。
  • 样本来自三级医疗中心,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the diagnostic accuracy of multiparametric magnetic resonance imaging and multiparametric magnetic resonance imaging/transrectal ultrasound fusion guided targeted biopsy against that of transperineal template saturation prostate biopsy to detect prostate cancer. MATERIALS AND METHODS: We retrospectively analyzed the records of 415 men who consecutively presented for prostate biopsy between November 2014 and September 2016 at our tertiary care center. Multiparametric magnetic resonance imaging was performed using a 3 Tesla device without an endorectal coil, followed by transperineal template saturation prostate biopsy with the BiopSee® fusion system. Additional fusion guided targeted biopsy was done in men with a suspicious lesion on multiparametric magnetic resonance imaging, defined as Likert score 3 to 5. Any Gleason pattern 4 or greater was defined as clinically significant prostate cancer. The detection rates of multiparametric magnetic resonance imaging and fusion guided targeted biopsy were compared with the detection rate of transperineal template saturation prostate biopsy using the McNemar test. RESULTS: We obtained a median of 40 (range 30 to 55) and 3 (range 2 to 4) transperineal template saturation prostate biopsy and fusion guided targeted biopsy cores, respectively. Of the 124 patients (29.9%) without a suspicious lesion on multiparametric magnetic resonance imaging 32 (25.8%) were found to have clinically significant prostate cancer on transperineal template saturation prostate biopsy. Of the 291 patients (70.1%) with a Likert score of 3 to 5 clinically significant prostate cancer was detected in 129 (44.3%) by multiparametric magnetic resonance imaging fusion guided targeted biopsy, in 176 (60.5%) by transperineal template saturation prostate biopsy and in 187 (64.3%) by the combined approach. Overall 58 cases (19.9%) of clinically significant prostate cancer would have been missed if fusion guided targeted biopsy had been performed exclusively. The sensitivity of multiparametric magnetic resonance imaging and fusion guided targeted biopsy for clinically significant prostate cancer was 84.6% and 56.7% with a negative likelihood ratio of 0.35 and 0.46, respectively. CONCLUSIONS: Multiparametric magnetic resonance imaging alone should not be performed as a triage test due to a substantial number of false-negative cases with clinically significant prostate cancer. Systematic biopsy outperformed fusion guided targeted biopsy. Therefore, it will remain crucial in the diagnostic pathway of prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mortezavi A, Märzendorfer O, Donati OF, et al. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer. J Urol. 2018. PMID: 29474846. doi:10.1016/j.juro.2018.02.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。